Interferon gamma News and Research

RSS

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated the efficacy of a novel biopolymer, N-dihydrogalactochitosan (GC), as an adjuvant for next-generation mucosal coronavirus disease 2019 (COVID-19) vaccine.

12 Sep 2022

A direct side-by-side comparison of all available COVID-19 vaccines

In a recent study posted to the medRxiv* preprint server, researchers assessed immune responses to homologous and heterologous coronavirus disease 2019 (COVID-19) vaccine combinations among Córdoba, Spain residents.

11 Sep 2022

How does SARS-CoV-2 affect the male genitourinary system?

In a recent paper published in the American Journal of Clinical and Experimental Urology, researchers reviewed existing data on the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on the male genitourinary (GU) tract.

7 Sep 2022

What is the association between T lymphocyte-mediated immune responses and COVID-19 severity?

Researchers examined the relationship between cell-mediated or T lymphocyte-mediated immunity and SARS-CoV-2 infection severity.

25 Aug 2022

The role of SARS-CoV-2-specific T cells induced by infection, vaccination, or their combination in disease protection

Researchers evaluated how SARS-CoV-2-specific-T lymphocytes induced by infection, vaccination, or both conferred protection against severe COVID-19.

24 Aug 2022

Memory B and T cell responses to the SARS-CoV-2 spike protein before and after the third BNT162b2 booster

Researchers evaluated memory B and T cell responses to SARS-CoV-2 before and after the third dose of the BNT162b2 vaccine.

3 Aug 2022

Tannins as therapeutic agents against SARS-CoV-2

Researchers reviewed tannins as therapeutic agents against SARS-CoV-2.

29 Jul 2022

Study highlights impaired ketogenesis as a potential confounder of severe COVID-19

In severe Covid-19 patients, the metabolism produces insufficient amounts of certain energy-rich compounds called ketone bodies. However, these energy carriers are needed by two important cell types in the immune system in order to fight the virus effectively.

28 Jul 2022

Cytokine-based cancer immunotherapy: current progress and future prospects

In this interview, News-Medical talks to Dr. Shuang Zhou about cytokine-base cancer immunotherapy, the current state of the field, and future prospects.

From Sino Biological Inc. 18 Jul 2022

Study shows that older adults can generate robust, long-lived memory against SARS-CoV-2 following infection

Researchers reported on the benefit of immunity developed by previous SARS-CoV-2 infection for overcoming the age-associated decline in COVID-19 vaccine effectiveness.

18 Jul 2022

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy and durability of immune responses to the third dose of coronavirus disease 2019 (COVID-19) vaccines. They also assessed the efficacy of the fourth vaccine dose among severely immunocompromised patients with hematological malignancies.

7 Jul 2022

What role does human microbiota play in COVID-19 severity?

In a recent study published in the journal Advanced Science, researchers explored the dynamic changes in the respiratory tract and gut microbiota in coronavirus disease 2019 (COVID-19) patients. They observed and analyzed these changes during different disease progression stages among patients with differential disease severities.

5 Jul 2022

Mild COVID causes increase in neurotoxic metabolites

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the blood levels of neurotoxic metabolites in patients with mild coronavirus disease 2019 (COVID-19).

23 Jun 2022

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.

21 Jun 2022

Demonstrating varying pathogenicity and tropism of SARS-CoV-2 variants in a feline model

In a recent study posted to the bioRxiv* pre-print server, researchers at Cornell University College of Veterinary Medicine and the University of Illinois Urbana-Champaign compared the infection dynamics, pathogenicity, and tissue tropism of multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in adult cats.

17 Jun 2022

New test can tell if you are immune to SARS-CoV-2

In a recent study published in the journal Nature Biotechnology, an international team of researchers developed and evaluated quantitative polymerase chain reaction (qPCR)-based assays to quantify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific functional T cell immunity.

15 Jun 2022

Animal study suggests intranasal COVID vaccine delivery more efficient than intramuscular

In a recent study published in the journal PNAS, researchers demonstrated higher comparative efficacy of the intranasal (IN) route of coronavirus disease 2019 (COVID-19) vaccine administration versus intramuscular route in mice.

12 Jun 2022

Cognitive impairment and function in SARS-CoV-2 positive patients

Researchers assessed the association between post-acute COVID-19 cognitive impairment and kynurenine pathway activation.

9 Jun 2022

SARS-CoV-2 ORF8 protein binds to dendritic cells and induces a hyper-inflammatory cytokine storm

In a recent study posted to the bioRxiv* pre-print server, researchers examined how the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) open reading frame 8 (ORF8) protein with host dendritic cells (DCs) induced cytokine storm.

8 Jun 2022

Immunogenicity of BNT162b2 COVID-19 vaccine in melanoma patients receiving immunotherapy

In a recent study under review at the Scientific Reports journal and posted to the Research Square* preprint server, researchers evaluated the efficacy of messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine BNT162b2 in cancer patients under treatment with immune checkpoint inhibitors (ICIs).

25 May 2022